Morphotek and Fox Chase Cancer Centre (FCCC) have entered a sponsored research agreement (SRA) to advance research on immunosuppressive effects of tumour shed antigens to develop improvised cancer therapies.
According to the agreement, the partners will jointly work on expanding knowledge of the biological pathways to identify tumour molecular and cellular signatures and suppressed immune responses in patients to tumours during immune-based therapies.
The agreement enables the two partners to further study the efficacy of the therapies.
PRA Health Sciences and Takeda Pharmaceutical Company have entered an agreement to further advance the development of the latter’s product pipeline, clinical studies of marketed products and post-approval needs.
Pursuant to the agreement, PRA Health Sciences will support the pipeline studies for Takeda by using its internal resources and will also provide regulatory pharmacovigilance services for its marketed and development product line.
Celon Pharma plans to raise gross proceeds of $63.3m through the initial public offering (IPO) of 15 million of its series B shares.
The company plans to use the proceeds to fund its clinical studies programme.
Agios Pharmaceuticals has announced an underwritten public offering of its common stock shares. The company expects to raise up to $150m through the offering.
The pharmaceutical company plans to use the proceeds for general corporate purposes and to further advance its ongoing development and pre-commercial activities of AG-120 and AG-221, PK deficiency programme, and early candidate programme.
Avitide plans to expand its affinity resin discovery platform and manufacturing operations through the funds raised from a Series D venture financing round.
The financing round was led by Mithril Capital Management.
Image: PRA Health Sciences and Takeda Pharmaceutical Company have entered an agreement to further advance the development of the latter's product development. Photo: courtesy of Lombroso via Wikipedia.